Shandong Xinhua Receives Key Drug Approval
Company Announcements

Shandong Xinhua Receives Key Drug Approval

Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.

Shandong Xinhua Pharmaceutical Company Limited has received approval from China’s National Medical Products Administration for a supplementary drug application concerning the diprophylline injection, marking a significant step in the transfer of marketing authorization. The approval follows a technology transfer agreement with Nanjing Kangfa Biotechnology Co., Ltd., allowing Xinhua Pharmaceutical to acquire significant rights and interests related to the drug’s marketing and sales. This development could potentially influence the company’s stock performance as it expands its pharmaceutical portfolio.

For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharmaceutical Announces December EGM
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharma Secures Key Drug Approval
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua’s Generic Drug Receives Key Approval
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App